Avatar

About Richard Knight

Dr Richard Knight PhD, ERT. A co-founder of ApconiX, Richard is an expert toxicologist with more than 20 years of drug development experience gained in AstraZeneca, where he was part of the Drug Safety and Oncology Leadership Teams. Richard has worked on projects in multiple therapy areas involving small molecules, biologics, proteins and oligonucleotides. He has an in-depth understanding of drug discovery and drug development and has been directly involved in bringing over 35 new candidate drugs to clinical trials and 6 to marketing approval. He uses his extensive experience to bring an innovative, science-led and pragmatic approach to the design and delivery of nonclinical safety programmes.

Dr Laurence Bishop Attends Bio-Europe Digital 2020

Dr Laurence Bishop is attending Bio-Europe Digital 2020 from the 26th to the 29th of October. Dr Michael Morton and Dr Richard Knight joined the UK delegation at The UK Pavilion at BIO-Europe last year.  ApconiX benefited from a Tradeshow Access Programme (TAP) grant offered by the Department of International Trade.   “I have fond [...]

By |2020-10-21T15:39:55+01:00October 21st, 2020|Events|Comments Off on Dr Laurence Bishop Attends Bio-Europe Digital 2020

Dr Laurence Bishop Attends BioJapan Online

Dr Laurence Bishop will be attending BioJapan online between 14th and the 16th of October 2020. BioJapan is being held at the Pacifico Yokohama in Japan this year and will be a hybrid of partnering taking place online and onsite. Some companies are exhibiting live and there will also be a mixture of live and [...]

By |2020-10-08T16:38:40+01:00October 8th, 2020|Events|Comments Off on Dr Laurence Bishop Attends BioJapan Online

ApconiX Welcomes Simon Craige to the Team

ApconiX is delighted to welcome Simon Craige to the team. Simon has over 15 years’ nonclinical and toxicology experience working in several medical and pharmaceutical organisations across multiple disciplines including small molecules, vaccines, biologics, and medical devices.  He has experience of a diverse range of therapeutic areas including oncology, CNS, ocular and dermal in drug [...]

By |2020-10-12T17:30:30+01:00September 30th, 2020|Careers|Comments Off on ApconiX Welcomes Simon Craige to the Team

ApconiX Welcomes Dr Duncan Armstrong

ApconiX is delighted to welcome Dr Duncan Armstrong to the team. Duncan has expert knowledge in molecular pharmacology, preclinical safety pharmacology and secondary pharmacodynamics gained over 18 years working in drug discovery and development at AstraZeneca UK and Novartis USA. He has worked with project teams across multiple therapy areas and at all stages of [...]

By |2020-09-09T14:15:45+01:00September 9th, 2020|Careers|Comments Off on ApconiX Welcomes Dr Duncan Armstrong

ApconiX Welcomes Dr Laurence Bishop

ApconiX is delighted to welcome Dr Laurence Bishop to the team as our Head of Business Development.  Laurence is an experienced DMPK and toxicological scientist with 20 years’ experience of nonclinical drug development.  Specialising in business development for the past 13 years, we are looking forward to Laurence playing a key role in our growth [...]

By |2020-05-28T17:27:19+01:00May 28th, 2020|Careers|Comments Off on ApconiX Welcomes Dr Laurence Bishop

Dr Guy Healing Appointed Honorary Professor

ApconiX is pleased to announce that Dr Guy Healing has been appointed to an Honorary Professorship in the School of Pharmacy at the University of East Anglia (UEA), Norwich, UK. Guy first became involved with the UEA when he worked for AstraZeneca.  One of the University’s PhD projects was co-sponsored by AstraZeneca and Guy was [...]

By |2020-05-20T14:26:09+01:00May 20th, 2020|Nonclinical Study Monitoring|Comments Off on Dr Guy Healing Appointed Honorary Professor

COVID-19 Update

As we all continue to live through these very difficult times, our main priority is the safety and wellbeing of our staff, their families and the community.  As an essential facility in the development of new medicines, we remain fully operational.  We are following government guidelines and are keeping all our clients updated as the [...]

By |2020-04-08T16:21:17+01:00April 8th, 2020|Events|Comments Off on COVID-19 Update

ApconiX Welcomes Olivia Turner

ApconiX welcomes Olivia Turner to the team.   Olivia has just finished her second year studying Biomedical Sciences at The University of Sheffield and will be working at ApconiX as an industry placement student until Christmas.  She will then join Aptus Clinical and continue her placement until the end of June. Choosing to take the Physiology [...]

By |2019-10-22T13:28:04+01:00October 16th, 2019|Careers|Comments Off on ApconiX Welcomes Olivia Turner

ApconiX Are in Boston, USA at the End of August

Dr Richard Knight and Professor Ruth Roberts are travelling to Boston at the end of August to meet with old colleagues and new contacts, promoting the company’s services in Project Toxicology, Ion Channel Screening and Assay Development, Target Safety Assessments and all aspects of Nonclinical Programme Design. They will be joined by Dr Andrew Winkley. [...]

By |2019-08-20T17:40:25+01:00August 20th, 2019|Ion Channels, Target Safety Assessments, Toxicology, Events|Comments Off on ApconiX Are in Boston, USA at the End of August

ApconiX Welcomes William O’Brien

ApconiX is delighted to welcome William O'Brien as their new Finance Director.  William has a strong background in high-tech development management and corporate finance. William is the founder of WOCO, a specialist R&D tax and financial advisory business based at Alderley Park, Cheshire.  A seasoned leader, he previously worked across a wide range of industries [...]

By |2019-06-12T10:08:57+01:00June 26th, 2019|Careers|Comments Off on ApconiX Welcomes William O’Brien